NICE announces guidelines for use of rituximabBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7418.766-a (Published 02 October 2003) Cite this as: BMJ 2003;327:766
- Susan Mayor
The National Institute for Clinical Excellence (NICE) has recommended that rituximab should be included in the treatment of patients with moderate to advanced B cell non-Hodgkin's lymphoma—the more aggressive form of lymphoma—and that the drug should be evaluated in a clinical trial of patients with localised disease.
NICE—the body that advises the NHS in England and Wales on the use of drugs—recommended that rituximab should be used in combination with CHOP (the standard treatment for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial